Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Post by pabalooon Feb 20, 2019 3:30am
134 Views
Post# 29386493

BUY OUT?

BUY OUT?In just over 30 days the buyout of Synergy (Trulance) should be completed by Bausch which will complement there Xifaxan IBS medication. With Ciphers stock needing a tow truck to move I see be reason why Bausch wouldn’t make a bid to also hold the Trulance rights on both sides of the continent. When I look at the offer they paid for Synergy that was in bankruptcy protection 200 plus million I see no reason that a similar offer wouldn’t come ciphers way considering most of there products are also complimentary. Bausch already has the sales force and the reach to drive product sales Cipher would never be able to accomplish.  Think about the thousands of sales people driving the sales of these drugs and it’s win win as compared to the small force Cipher would implement. We should be getting a look at 4th quarter numbers soon and possibly some colour on future numbers that should start us moving up. 
Just a side note same house has been leaking the price down for the last 2 weeks a couple of hundred shares at a time. Hope there almost done we had traction just prior to the steel off.
Bullboard Posts